Aims: To investigate the effect of sildenafil on uroflowmetry values of patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic enlargement (BPE). Methods: Thirty-eight consecutive patients and 15 control subjects without voiding symptoms were enrolled in the study. All patients underwent uroflowmetry testing thrice on different occasions. The highest maximum urinary flow rate (Qmax) values with a sufficient voided volume (≧150 ml) were evaluated. The patients and controls were seen the day after the initial uroflowmetry measurements and were given 100 mg sildenafil. Afterwards uroflowmetry was repeated. The uroflowmetry values of both groups before and after sildenafil were compared. Results: Of the 38 patients, 29 (76%) showed improvement in flow rates. The mean Qmax was 11.4 ± 0.39 and 15.7 ± 0.74 ml/s before and after sildenafil, respectively (p < 0.0001). The mean percentage difference in Qmax was +38% higher after sildenafil. The mean average flow rate (Qave) and the mean voiding time values were also significantly improved. The mean voided volumes of the patients before and after sildenafil were 241 ± 78 and 264 ± 72 ml, respectively (p = 0.07). There were no significant differences in the Qmax, Qave and voided volumes of the control group. Conclusions: Sildenafil exhibits a significant improvement in Qmax and Qave rates in men with LUTS.

Keywords:
Benign prostate enlargement, Sildenafil, Uroflowmetry, Phosphodiesterase inhibitors
This content is only available via PDF.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.